We are live on ! Find out more
HF

HRT Financial Portfolio holdings

AUM $40.1B
1-Year Est. Return 58.22%
This Fund
S&P 500
This Quarter Est. Return
-1.05%
1 Year Est. Return
+58.22%
3 Year Est. Return
+133.11%
5 Year Est. Return
+158.39%
10 Year Est. Return
+582.8%
AUM
$212M
AUM Growth
+$134M
Cap. Flow
+$140M
Cap. Flow %
65.75%
Top 10 Hldgs %
59.84%
Holding
202
New
136
Increased
13
Reduced
6
Closed
46

Sector Composition

Rank Sector Weight
1 Real Estate 5.17%
2 Healthcare 2.63%
3 Financials 0.36%
4 Technology 0.08%
5 Energy 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VER
126
DELISTED
VEREIT, Inc.
VER
$168K 0.08%
+4,141
New +$187K
BCRX icon
127
BioCryst Pharmaceuticals
BCRX
$2.43B
$163K 0.08%
+10,973
New +$125K
MDXG icon
128
MiMedx Group
MDXG
$636M
$162K 0.08%
+13,981
New +$144K
SGDM icon
129
Sprott Gold Miners ETF
SGDM
$553M
$161K 0.08%
+10,163
New +$178K
NOK icon
130
Nokia
NOK
$51.8B
$160K 0.08%
23,482
-28,344
-55% -$207K
PGNX
131
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$152K 0.07%
+20,502
New +$124K
KERX
132
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$152K 0.07%
+15,299
New +$164K
OREX
133
DELISTED
Orexigen Therapeutics, Inc.
OREX
$149K 0.07%
+3,020
New +$181K
ARNA
134
DELISTED
Arena Pharmaceuticals Inc
ARNA
$148K 0.07%
+3,197
New +$139K
ACGN
135
DELISTED
Aceragen Inc
ACGN
$146K 0.07%
+290
New +$133K
XOMA
136
DELISTED
Xoma
XOMA
$143K 0.07%
+1,855
New +$134K
VALE.P
137
DELISTED
Vale S A
VALE.P
$143K 0.07%
28,499
-29,914
-51% -$167K
MACK
138
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$142K 0.07%
+1,468
New +$140K
EXEL icon
139
Exelixis
EXEL
$14B
$141K 0.07%
+37,616
New +$122K
ACHN
140
DELISTED
Achillion Pharmaceuticals
ACHN
$140K 0.07%
+15,865
New +$150K
RGLS
141
DELISTED
Regulus Therapeutics
RGLS
$139K 0.07%
+106
New +$171K
MNKD icon
142
MannKind Corp
MNKD
$1.22B
$138K 0.07%
+4,878
New +$125K
BDN
143
Brandywine Realty Trust
BDN
$535M
$136K 0.06%
+10,272
New +$149K
VNDA icon
144
Vanda Pharmaceuticals
VNDA
$314M
$132K 0.06%
+10,477
New +$113K
AGEN
145
Agenus
AGEN
$255M
$128K 0.06%
+759
New +$108K
ARRY
146
DELISTED
Array Biopharma Inc
ARRY
$128K 0.06%
+17,886
New +$132K
INO icon
147
Inovio Pharmaceuticals
INO
$79.4M
$127K 0.06%
+1,302
New +$139K
INFI
148
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$127K 0.06%
+11,675
New +$150K
SGMO
149
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$126K 0.06%
+11,400
New +$147K
SPPI
150
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$120K 0.06%
+17,662
New +$112K

Similar funds

HRT Financial's Q2 2015 Portfolio in Review

As of Q2 2015, HRT Financial held 202 positions worth $212M, up 172% from $78.1M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

HRT Financial deployed $140M of net new capital in Q2 2015, opening 136 new positions and adding to 13 existing holdings. Its largest new stake was iShares Expanded Tech-Software Sector ETF: 189,285 shares worth $3.76M.

By sector, the portfolio is most concentrated in Real Estate at 5.2% of assets, up from 1.9% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Invesco S&P 500 Low Volatility ETF, an estimated $2.8M trimmed.

  • HRT Financial's largest Q2 2015 buy was iShares Expanded Tech-Software Sector ETF: 189,285 shares worth $3.76M.
  • HRT Financial added most to VanEck Semiconductor ETF in Q2 2015, an estimated $57.5M increase.
  • HRT Financial's biggest Q2 2015 reduction was Invesco S&P 500 Low Volatility ETF, cutting an estimated $2.8M.
  • HRT Financial fully exited Invesco Water Resources ETF in Q2 2015, selling an estimated $3.89M.
  • HRT Financial's ten largest holdings make up 60% of its $212M portfolio in Q2 2015.
  • HRT Financial opened 136 new positions and closed 46 in Q2 2015.
  • HRT Financial's portfolio value rose 172% quarter-over-quarter to $212M.

Based on HRT Financial's 13F filing for Q2 2015, filed 13 Aug 2015.